Published Application/Species/Sample/Dilution | Reference |
---|
- blocking or activating experiments; mouse; ; fig 2d
| Aiken T, Erbe A, Zebertavage L, Komjathy D, Feils A, Rodriguez M, et al. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma. J Immunother Cancer. 2022;10: pubmed publisher
|
- blocking or activating experiments; mouse; fig s3k
| Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
|
- blocking or activating experiments; mouse; fig 10d
| Yoshikawa T, Taniguchi S, Kato H, Iwata Yoshikawa N, Tani H, Kurosu T, et al. A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome. PLoS Pathog. 2021;17:e1008859 pubmed publisher
|
- flow cytometry; mouse; loading ...; fig s2c
| Zhou T, Damsky W, Weizman O, McGeary M, Hartmann K, Rosen C, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583:609-614 pubmed publisher
|
| Lee J, Stone M, Porrett P, Thomas S, Komar C, Li J, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567:249-252 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...; fig s8
| Ruscetti M, Leibold J, Bott M, Fennell M, Kulick A, Salgado N, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362:1416-1422 pubmed publisher
|
- flow cytometry; mouse; loading ...; fig 7a
| Kortlever R, Sodir N, Wilson C, Burkhart D, Pellegrinet L, Brown Swigart L, et al. Myc Cooperates with Ras by Programming Inflammation and Immune Suppression. Cell. 2017;171:1301-1315.e14 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...; fig 3a
| Singh M, Vianden C, Cantwell M, Dai Z, Xiao Z, Sharma M, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8:1447 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...; fig s6a
| Billerbeck E, Wolfisberg R, Fahnøe U, Xiao J, Quirk C, Luna J, et al. Mouse models of acute and chronic hepacivirus infection. Science. 2017;357:204-208 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...; fig 6a
| Kwan B, Zhu E, Tzeng A, Sugito H, Eltahir A, Ma B, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med. 2017;214:1679-1690 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...; fig 6a
| Klein J, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, et al. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun. 2017;8:14600 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...
| Aguilera T, Rafat M, Castellini L, Shehade H, Kariolis M, Hui A, et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun. 2016;7:13898 pubmed publisher
|
- blocking or activating experiments; mouse; loading ...; fig s8
| Larocca R, Abbink P, Peron J, Zanotto P, Iampietro M, Badamchi Zadeh A, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536:474-8 pubmed
|
| Balogh K, Templeton D, Cross J. Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS ONE. 2018;13:e0197702 pubmed publisher
|
| Li J, Lee Y, Li Y, Jiang Y, Lu H, Zang W, et al. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. Immunity. 2018;48:773-786.e5 pubmed publisher
|
| Topper M, Vaz M, Chiappinelli K, Destefano Shields C, Niknafs N, Yen R, et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell. 2017;171:1284-1300.e21 pubmed publisher
|
| Moynihan K, Opel C, Szeto G, Tzeng A, Zhu E, Engreitz J, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402-1410 pubmed publisher
|
| Zhang Y, Velez Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed publisher
|
| Vanpouille Box C, Diamond J, Pilones K, Zavadil J, Babb J, Formenti S, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75:2232-42 pubmed publisher
|
| Coffelt S, Kersten K, Doornebal C, Weiden J, Vrijland K, Hau C, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345-348 pubmed publisher
|
| Twyman Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher
|
| Yamada D, Elsaesser H, Lux A, Timmerman J, Morrison S, de la Torre J, et al. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015;42:379-390 pubmed publisher
|
| Evans E, Jonason A, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015;3:689-701 pubmed publisher
|
| Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139-48 pubmed publisher
|
| Van der Jeught K, Joe P, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget. 2014;5:10100-13 pubmed
|
| Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol. 2014;15:758-66 pubmed publisher
|
| Deberge M, Ely K, Enelow R. Soluble, but not transmembrane, TNF-? is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology. J Immunol. 2014;192:5839-51 pubmed publisher
|
| Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-95 pubmed publisher
|
| Kearl T, Jing W, Gershan J, Johnson B. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol. 2013;190:5620-8 pubmed publisher
|
| Sandoval F, Terme M, Nizard M, Badoual C, Bureau M, Freyburger L, et al. Mucosal imprinting of vaccine-induced CD8? T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med. 2013;5:172ra20 pubmed publisher
|
| Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res. 2012;18:4092-103 pubmed publisher
|
| Quezada S, Simpson T, Peggs K, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637-50 pubmed publisher
|